1. 1. FDAInformation for Health Care Professionals: Gadolinium-based Contrast Agents for Magnetic Resonance Imaging(6/2006, Updated 12/2006 and 5/23/2007) [Cited 25 August 2007.] Available from URL: http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705HCP.pdf
2. 2. MHRA.Letter to Health Care Professionals: Risks of Nephrogenic Fibrosing Dermopathy or Nephrogenic Systemic Fibrosis(10/08/2006). [Cited 25 August 2007.] Available from URL: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGEuseSecondary=truessDocName=CON2024695ssTargetNodeId=221
3. 3. SE Cowper, HS Robin, SM Steinberg, LD Su, S Gupta, and PE. LeBoit, Scleromyxoedema-like cutaneous diseases in renal-dialysis patients . 2000 ; 356 : 1000 -01 .
4. 4. SE Cowper .Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2007.[Cited 25 August 2007.] Available from URL: http://www.icnfdr.org
5. 5. L. Gordis, Epidemiology , 3rd edn . Philadelphia, PA: Elsivier Saunders, 2004 .